WJ01 XPO1 inhibitor

An uniquely designed covalent XPO1 inhibitor of rapid clearance with broad-spectrum antitumor activity. It can be used to treat a variety of hematological cancers and solid tumors in clinic.

WJ02 EGFR inhibitor

A small molecule EGFR inhibitor that effectively inhibits the Exon 20 insertion mutations. Preclinical data show that WJ002 maintains the activity of inhibiting common EGFR mutations such as T790M, and at the same time overcomes the insensitivity of the 3rd EGFR inhibitor to exon20 insertion mutations.

WJ03 Aurora A inhibitor

An oral available small molecule Aurora A inhibitor. Aurora A inhibitors have a synthetic lethal effect with RB1 deletion or inactivation, and can be used to treat malignant tumors with RB1 deletion or inactivation such as small cell lung cancer and triple-negative breast cancer.

WJ04 EGFR inhibitor

An effective fourth-generation EGFR inhibitor. Preclinical data show that the drug has a good inhibitory activity against acquired EGFR mutations, including Del19/T790M/C797S and L858R/T790M/C797S that are insensitive to third-generation EGFR inhibitors, and shows high selectivity over wild-type EGFR.

WJ05 Wee1 inhibitor

Undisclosed

WJ06 FAK inhibitor

Undisclosed

WJ07 KIF18A inhibitor

Undisclosed

WJ08

Undisclosed

WJ09

Undisclosed

WJ10

Undisclosed

WJ11

Undisclosed